It has been around a year since Beam Therapeutics slashed its headcount and R&D programmes to focus mainly on a sickle cell disease candidate – and the biotech has now revealed the first data with the ...
Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...
Abstract: Base station (BS) sleeping is an effective way to reduce the energy consumption of mobile networks. Previous efforts to design sleeping control algorithms mainly rely on stochastic traffic ...
Beam is now in the strongest position of all companies advancing a genetic therapy for alpha-1 antitrypsin deficiency, according to analysts at William Blair. Beam Therapeutics’ investigational base ...
Beam Therapeutics said Wednesday its study of a gene editing treatment for alpha-1 antitrypsin deficiency helped restore protein production in patients with the rare liver and lung disease, the most ...
Abstract: Efficient acceleration of Deep Neural Networks is a manifold task. In order to save memory requirements and reduce energy consumption we propose the use of dedicated accelerators with novel ...
MOABS has been deployed in https://anaconda.org/bioconda/moabs. To install MOABS from Bioconda, the following channels should be added. Namely, conda config --add ...
Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results